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Abstract
Being male or female is an important determinant of risks for certain diseases, patterns of illness and life expectancy.
Although differences in risks for and prognoses of several diseases have been well documented, sex-based differences in
responses to pharmaceutical treatments and accompanying risks of adverse events are less clear. The objective of this
umbrella review was to determine whether clinically relevant differences in efficacy and safety of commonly prescribed
medications exist between men and women. We retrieved all available systematic reviews of the Oregon Drug Effectiveness
Review Project published before January 2010. Two persons independently reviewed each report to identify relevant
studies. We dually abstracted data from the original publications into standardized forms. We synthesized the available
evidence for each drug class and rated its quality applying the GRADE (Grading of Recommendations Assessment,
Development and Evaluation) approach. Findings, based on 59 studies and data of more than 250,000 patients suggested
that for the majority of drugs no substantial differences in efficacy and safety exist between men and women. Some
clinically important exceptions, however, were apparent: women experienced substantially lower response rates with newer
antiemetics than men (45% vs. 58%; relative risk 1.49, 95% confidence interval 1.35–1.64); men had higher rates of sexual
dysfunction than women while on paroxetine for major depressive disorder; women discontinued lovastatin more
frequently than men because of adverse events. Overall, for the majority of drugs sex does not appear to be a factor that
has to be taken into consideration when choosing a drug treatment. The available body of evidence, however, was limited
in quality and quantity, confining the range and certainty of our conclusions.
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Introduction
Being male or female is an important determinant of societal
roles, individual and health behaviors, risks for certain diseases, as
well as patterns of illness and life expectancy. In recent years, the
importance of potential differences between men and women has
resulted in considerable effort to understand the role of sex in
health and disease [1,2,3].
In 2001 the United States(U.S.) Institute of Medicine released a
report that confirmed differences between men and women in the
prevalence and severity of a broad range of diseases and conditions
[3]. For example, depression, irritable bowel syndrome, urinary
incontinence, or osteoporosis affect women more commonly than
men, while coronary artery disease, autism, and learning
disabilities occur more frequently in males than in females.
Nonetheless, the exact differences between men and women at the
genetic, cellular, or functional levels of the body are largely
unknown. Indeed, for some diseases, for example psychiatric
disorders, differences in gender (i.e., a person’s self representation
as a man or woman and how that person is responded to by social
institutions) might be more important than differences in sex (i.e.,
the classification by reproductive organs and chromosomal
complement) [3]. Sex-based medicine promises to take the unique
biological and physiological differences between the sexes into
consideration to deliver better and more targeted health care.
Although differences in risks for and prognoses of several
diseases have been well documented [4,5,6,7], sex-based differ-
ences in responses to pharmaceutical treatments and accompany-
ing risks of adverse events are less clear. Variations in absorption,
distribution, metabolism, and excretion of pharmaceuticals
between men and women have been investigated and demon-
strated for various drugs. For example, the clearance of
methylprednisolone is greater in men than in women during the
late luteal cycle [8]. Similarly, isoproterenol exhibits a dose-
response gradient to vasodilation in men but not in women [9].
The majority of these findings indicate differences on physiolog-
ical, pharmacodynamic, or pharmacokinetic outcomes and are
mostly attributed to hormonal fluctuations. Whether such findings
translate into clinically relevant differences in efficacy and safety of
pharmacological treatments remains undetermined.
The Drug Effectiveness Review Project (DERP) was founded in
2003 by the Center for Evidence-based Policy of the Oregon
Health and Science University to provide policy-makers with
the best available evidence regarding the comparative efficacy,
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Ten U.S. States and Canada currently contribute to this initiative.
DERP reports are high quality systematic reviews that are
standardized in methods and structure. They undergo extensive
peer and public review before being finalized. To date, DERP has
covered 36 commonly prescribed classes of medications. A specific
feature of DERP reports is that authors are required to assess
differences in the efficacy and safety of drugs in various subgroups,
one of which is always sex.
The objective of our review was to determine whether clinically
relevant differences in efficacy and safety exist between men and
women when treated with commonly prescribed medications.
Materials and Methods
Drug class reviews
We retrieved the latest updates of all publicly available DERP
drug class reviews up to January 2010 from the project’s website
[11]. We excluded one report because the population of interest
was women only (hormone therapy for postmenopausal women).
The drug classes covered in the 35 included reports, the year of the
last update, indications of interest, and the 300 included
medications are listed in table S1.
Two persons independently reviewed the subgroups chapter of
each report to assess whether evidence on differential treatment
effects between men and women was reported. Any relevant
information with respect to sex as an effect modifier was abstracted
into standardized forms and dually reviewed. Discrepancies
between reviewers were resolved by consensus or by consulting a
third person. If the available information in the report was
incomplete or erroneous, we contacted the authors and asked for
clarification.
Individual study analysis
We retrieved and assessed full-text copies of all relevant
publications identified in the subgroups chapters as providing
information on the impact of sex, regardless of study design and
duration. We excluded studies that were rated as having poor
methodological quality by the authors of the reports as well as
studies published as abstracts-only because of the limited
information available on methods.
One reviewer abstracted pertinent data from each study into a
standardized data abstraction form. Items of interest included:
study design, number of participating men and women, charac-
teristics of included population and indications, outcomes of
interest, methods of outcomes and adverse events assessment,
statistical approach regarding subgroup analyses, and results. A
second reviewer cross-checked the abstracted information. Differ-
ences were resolved by consensus.
Our main outcomes of interest across all indications and drug
classes were endpoints that could be viewed as health outcomes
(i.e., any outcome that a patient can feel or experience). We
included surrogate and intermediate outcome measures only if no
relevant health outcomes were available.
Data synthesis
We grouped the data from each drug class according to
indication. If data were sufficient we calculated relative risks and
95% confidence intervals as summary statistics comparing
treatment effects between men and women. If more than two
studies within the same drug class examined the same outcome in
a similar population, we conducted meta-analyses to achieve a
pooled estimate of the effect. For each meta-analysis we ran a test
of heterogeneity (I
2 index) and applied both random and fixed
effects models. We assessed publication bias by using funnel plots
and Begg’s adjusted correlation tests. All statistical analyses were
done in StatsDirect Statistical Software program, version 2.7.7
(StatsDirect, Sale, United Kingdom).
If a particular study was included in a meta-analysis or pooled
data analysis of good or fair quality, we did not incorporate this
study again in the synthesis of the evidence. Where pooling was
not possible we summarized the evidence qualitatively and present
point estimates from the best available evidence.
Classification of the effect of sex
We classified differences between men and women as ‘‘insignif-
icant’’, ‘‘favors men’’, ‘‘favors women’’, or ‘‘conflicting’’. The
classification ‘‘insignificant’’ was used for direct comparisons
between men and women that did not render a statistically
significant difference. If no direct comparisons were available, we
assessed point estimates of stratified treatment effects. We classified
differences as ‘‘insignificant’’ if point estimates of relative treatment
effects of men and women were within a range of 25% relative risk
reduction or increase. We classified the evidence as ‘‘favors men’’ or
‘‘favors women’’ when direct comparison demonstrated a statisti-
cally significant difference in efficacy or risks of adverse events or
when differences in point estimates of relative treatment effects were
outside a range of 25% relative risk reduction or increase. If results
on different outcomes within the same study were conflicting or if
studies of similar internal validity rendered contradicting findings,
we classified the evidence as ‘‘conflicting’’.
Rating the quality of the evidence
Two persons rated the quality of the available evidence in a four
part hierarchy (high, moderate, low, very low) based on an
approach devised by the GRADE (Grading of Recommendations
Assessment, Development and Evaluation) Working Group using
the GRADE Profiler [12,13]. This approach incorporates four key
elements: study limitations (in design and conduct), consistency of
findings of the underlying evidence, directness of its relationship to
the medical practice under consideration, and precision of results.
Ratings reflect the quality of the body of evidence to support or
reject the notion that differences in treatment effects (beneficial or
adverse) exist between men and women for a specific indication.
Discrepancies in ratings were resolved by consensus.
Results
Eighteen of the 35 drug class reviews identified evidence
concerning the impact of sex on the efficacy and safety of drugs.
Overall, we retrieved 59 studies that addressed our question of
interest, including data on over 250,000 patients. These studies
provide evidence on 65 individual medications (23% of all
medications in the drug class reviews, see table S1). Figure 1
presents the flow of reports and publications and summarizes the
number of outcomes for which high, moderate, or low/very low
quality evidence was available.
For most indications the available evidence was compromised
by methodological limitations. Differences in the efficacy and risks
of adverse events between men and women were rarely compared
directly. Most commonly, variations in treatment effects between
the sexes were examined within a multitude of subgroup analyses
and very few studies employed tests of interaction to determine
pre-specified subgroup effects.
The impact of sex on efficacy
In total, 53 studies assessed the impact of sex on the efficacy of
medications. These studies provided information on 68 drugs used
Sex and Drug Outcomes
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demonstrated similar treatment effects between men and women.
With the exception of one drug class (newer antiemetic drugs),
studies that reported better responses to treatment for either men
or women were generally of small sample size or had
methodological shortcomings.
Table S2 summarizes the available evidence, relevant outcomes,
and the quality of the evidence for each drug class and relevant
indications. We rated the quality of the evidence for 18 indications
as low or very low which implies that results are uncertain und
very likely to be changed by new studies. The evidence on drug
classes for six indications was rated as moderate, suggesting that
current findings are still likely to be altered by new evidence.
Seven drug classes used for the treatment of 12 indications
received a rating of high-quality : (1) Angiotensin converting
enzyme inhibitors (ACE-inhibitors) in patients with chronic heart
failure; (2) angiotensin II receptor blockers (ARBs) in patients with
chronic heart failure; (3) beta-blockers for patients with myocardial
infarction and for patients with left ventricular systolic dysfunction;
(4) newer antiplatelet agents for patients with coronary artery
disease; (5) statins in persons with hypercholesteremia; (6) second-
generation antidepressants for the treatment of major depressive
disorder; and (7) newer antiemetic agents for the prevention of
chemotherapy-induced nausea and emesis. A rating of high quality
of evidence indicates that results are unlikely to be changed by
future studies.
In the following paragraphs we summarize the available
evidence for drugs and indications that were supported by
evidence of high quality. Figure 2 depicts treatment effects for
men and women of medications for which conclusions are
supported by high-quality evidence.
Meta-analysis: Newer antiemetic agents for the
prevention of chemotherapy-induced nausea and emesis.
Newer antiemetic agents (dolasetron, granisetron, ondansatron) is
the only drug class where high-quality evidence supports
differences in treatment effects between men and women. Men
undergoing chemotherapy frequently responded better to
prophylactic treatment with newer antiemetics than women
[14,15,16,17,18,19,20]. We pooled response rates (prevention of
nausea and vomiting) comparing men with women for different
dosing regimens of dolasetron, granisetron, and ondansatron
(figure 3). Results based on 20 treatment arms (seven randomized
controlled trials [RCTs]) with data on more than 4900 patients
indicated that, on average, 58% of men compared with 45%
of women responded to treatment (relative risk 1.49, 95% CI
1.35–1.64).
ACE-inhibitors in patients with chronic heart failure.
Two well conducted meta-analyses of ACE-inhibitors in more
than 19,000 patients [21–22] yielded similar reductions in heart
failure mortality between men (OR 0.76, 95% CI 0.65–0.88) and
women (OR 0.79, 95% CI 0.59–1.06) compared with placebo
[22].
ARBs in patients with chronic heart failure. Three
subgroup analyses of male and female patients with heart failure
treated with ARBs [23,24,25], indicated beneficial effects on
mortality irrespective of sex. For example, the hazard ratio for
mortality was 0.87 for men vs. 0.88 for women (test for interaction
p=0.87) [24].
Beta-blockers for patients with chronic heart failure or
myocardial infarction. One meta-analysis of male and female
patients with chronic heart failure treated with bispropolol,
carvedilol, and metoprolol [26], calculated similar reductions in
mortality rates for men (RR 0.66, 95% CI 0.59–0.75) and women
(RR 0.63, 95% CI 0.44–0.91) compared with placebo. Likewise,
beta-blockers exhibited similar benefits in male and female
patients with post-myocardial infarction. Two pooled analyses of
RCTs yielded similar reductions in mortality for men (OR 0.74,
95% CI not reported) and women (OR 0.81, 95% CI not
reported) [27,28].
Statins in persons with hypercholesteremia. Treatment
effects were similar between the sexes with respect to major
coronary effects and cardiovascular disease mortality in patients
with hypercholesteremia treated with statins. One well-conducted
meta-analysis reported a similar relative and absolute risk
reduction of major coronary effects between men and women
treated with statins (number needed to treat [NNT] for men 27,
95% CI 23–43; NNT for women 31, 95% CI 19–75) [29].
Newer antiplatelet agents for patients with coronary
artery disease. Three subgroup analyses of RCTs[30,31,32]
of patients with coronary artery disease treated with clopidogrel
Figure 1. Flow of reports and publications and the number of outcomes for which high, moderate or low quality evidence was
available.
doi:10.1371/journal.pone.0011895.g001
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doi:10.1371/journal.pone.0011895.g002
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myocardial infarction in men (RR 0.65, 95%CI 0.48–0.87) and
women (RR 0.77, 95%CI 0.52–1.15) [32].
Second-generation antidepressants for major depressive
disorder. A pooled analysis of eight RCTs on more than 3,500
patients with major depressive disorder detected similar remission
rates for men (36%) and women (36%) treated with fluoxetine,
fluvoxamine, or paroxetine [33]. Likewise, male and female
patients treated with venlafaxine for major depressive disorder
achieved similar remission rates (45% vs. 45%) [34].
The impact of sex on the risk of adverse events
We included 11 studies that assessed the impact of sexon the risks
of adverse events of medications. These studies provided informa-
tionon16drugsused forthetreatmentofnine indications.Table S3
summarizes the quality of the available evidence for adverse events.
Methodological limitations compromised all available studies
for adverse events. No high quality evidence could be identified for
any of the drug classes and indications. Moderate-quality evidence
indicates that men experience more sexual adverse events with
paroxetine and that more women withdraw from trials due to
adverse events when taking lovastatin.
Specifically, a pooled analysis of three RCTs of bupropion or
paroxetine for major depressive disorder reported that men treated
with paroxetine experienced higher rates of medication-related
sexual dysfunction than women (change in score on the Sexual
Functioning Questionnaire: men 24.14 vs. women +0.46; P =
not reported) [35]. In comparison, a similar improvement in
sexual dysfunction was reported for male and female patients
treated with bupropion.
In one large trial of patients treated with lovastatin, the risk for
women to discontinue treatment because of adverse events was
more than twice as high as in men (OR 2.5; 95% CI 1.5–4.2) [36].
Discussion
This umbrella review included information derived from 59
studies on more than 250,000 patients. For the majority of drugs
that had available evidence, sex does not appear to be a factor that
has to be taken into consideration when choosing a drug
treatment. Three clinically relevant exceptions, however, are
evident. Men achieved substantially better response rates than
women when treated with newer antiemetic drugs. This
information might be valuable to clinicians in anticipating the
need to move to second-line therapy in women who do not
Figure 3. Pooled response rates of men versus women for different dosages of newer antiemetics.
doi:10.1371/journal.pone.0011895.g003
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while undergoing chemotherapy. Likewise, treatment with parox-
etine led to substantially higher rates of sexual dysfunction in men
than in women, while no differences could be observed between
male and female patients treated with bupropion. Given similar
response and remission rates to second-generation antidepressants
[37,38], the higher risk of sexual dysfunction for men treated with
paroxetine should be taken into consideration when choosing an
antidepressant. Clinicians should also be aware that women are
more likely than men to discontinue statins due to adverse events.
Our study has some limitations. The available body of evidence
for most drug classes was limited in quality and quantity, confining
the range and the certainty of our conclusions. Only few results are
supported by high-quality evidence that is reliable enough to
assume that future studies will not change the estimates of the
effects. In particular, the methods of subgroup analyses were often
inadequate. They were typically conducted post hoc, sometimes
without correcting for multiple testing, increasing the risk of false
findings and incorrect conclusions [39]. Similarly, most studies
were not large enough to provide the statistical power to detect
differences between men and women.
In addition, in many trials the focus is on statistically significant
findings. Authors of studies may have chosen not to report
subgroup analyses by sex that did not yield statistically significant
differences (outcome reporting bias). In this case, our findings
would be distorted towards the existence of differences between
men and women, which was not the case.
We relied on completed drug class reviews and did not
reproduce the literature searches for each report. Authors of these
reviews may have incompletely summarized the evidence on sex.
We believe that it is unlikely that any missed studies would have
changed our conclusions because the methods of DERP include an
extensive peer and public review process. Nonetheless, it is possible
that new studies with relevant information have been more
recently published than the drug class reviews. For example, a
recent trial of statin therapy for primary prevention of cardiovas-
cular disease with more than17,000 participants did not
demonstrate a difference in the rate of adverse events between
men and women, which contrasts with our findings [40].
The scope of our review is limited to commonly prescribed
drugs that are of economic importance to participating organiza-
tions of the DERP project. Although a large variety of drugs have
been covered, some commonly used medications have not been
included. For some of these drugs, such as aspirin, evidence
suggests no clinically important differences in treatment effects
[41].
Although most of the results derived from high-quality evidence
indicate that differences in efficacy and risks of adverse events are
negligible, findings are not generalizable to other drug classes or
different indications.
Categorizing patients as ‘‘men’’ and ‘‘women‘‘ is based on
differences in societal roles, behavioral responses, risks for certain
diseases, and life expectancies. Nevertheless, neither men nor
women are homogenous groups and genetic variations between
and within the sexes may have a more important impact on
response to drug therapy than sex alone [42]. With the advance of
pharmacogenetics, future studies need to take relevant genetic
variations as potential confounders into consideration when
determining differences in efficacy and risks for adverse events
between men and women.
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